Sibyl Wray

1.4k total citations
58 papers, 628 citations indexed

About

Sibyl Wray is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Sibyl Wray has authored 58 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 17 papers in Immunology and 13 papers in Neurology. Recurrent topics in Sibyl Wray's work include Multiple Sclerosis Research Studies (33 papers), Immunotherapy and Immune Responses (12 papers) and Peripheral Neuropathies and Disorders (11 papers). Sibyl Wray is often cited by papers focused on Multiple Sclerosis Research Studies (33 papers), Immunotherapy and Immune Responses (12 papers) and Peripheral Neuropathies and Disorders (11 papers). Sibyl Wray collaborates with scholars based in United States, Germany and France. Sibyl Wray's co-authors include Edward Fox, Paul B. Farel, Krzysztof Selmaj, Michael Weiss, Matthew Gormley, Hans‐Peter Hartung, Amy E. Lovett‐Racke, Richard Shubin, Enrique Álvarez and B. Singer and has published in prestigious journals such as New England Journal of Medicine, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Sibyl Wray

55 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sibyl Wray United States	14	442	219	175	157	100	58	628
Trevor Pickersgill United Kingdom	13	675 1.5×	114 0.5×	230 1.3×	134 0.9×	156 1.6×	26	835
T. Pickersgill United Kingdom	8	582 1.3×	193 0.9×	253 1.4×	141 0.9×	192 1.9×	12	730
M. S. Freedman Canada	9	411 0.9×	105 0.5×	177 1.0×	108 0.7×	132 1.3×	16	536
Aurora Zanghì Italy	16	462 1.0×	132 0.6×	169 1.0×	174 1.1×	117 1.2×	50	648
Julia O’Mahony Canada	16	589 1.3×	149 0.7×	325 1.9×	102 0.6×	146 1.5×	43	840
N. А. Totolyan Russia	7	528 1.2×	196 0.9×	446 2.5×	60 0.4×	153 1.5×	50	720
Alexandra Degenhardt United Kingdom	9	655 1.5×	101 0.5×	243 1.4×	137 0.9×	218 2.2×	10	769
Annette Wundes United States	15	547 1.2×	161 0.7×	157 0.9×	265 1.7×	95 0.9×	35	813
Nils Koch-Henriksen Denmark	12	537 1.2×	161 0.7×	130 0.7×	118 0.8×	172 1.7×	16	706
Vilija Jokubaitis Australia	17	381 0.9×	285 1.3×	104 0.6×	112 0.7×	75 0.8×	55	816

Countries citing papers authored by Sibyl Wray

Since Specialization

Citations

This map shows the geographic impact of Sibyl Wray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sibyl Wray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sibyl Wray more than expected).

Fields of papers citing papers by Sibyl Wray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sibyl Wray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sibyl Wray. The network helps show where Sibyl Wray may publish in the future.

Co-authorship network of co-authors of Sibyl Wray

This figure shows the co-authorship network connecting the top 25 collaborators of Sibyl Wray. A scholar is included among the top collaborators of Sibyl Wray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sibyl Wray. Sibyl Wray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hauser, Stephen L., Jeffrey A. Cohen, J. de Sèze, et al.. (2025). Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. Neurology and Therapy. 14(5). 1975–1992. 2 indexed citations

Singer, B., Sibyl Wray, Mark Gudesblatt, et al.. (2024). Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and Therapy. 13(4). 1273–1285. 2 indexed citations

Álvarez, Enrique, Lawrence Steinman, Edward Fox, et al.. (2024). Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis. Frontiers in Neurology. 15. 1473284–1473284. 1 indexed citations

Jiang, Tammy, et al.. (2023). Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. CNS Drugs. 37(5). 441–452. 1 indexed citations

Wiendl, Heinz, Jeffrey Cohen, Ralf Gold, et al.. (2023). Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age (P6-3.016). Neurology. 100(17_supplement_2). 1 indexed citations

Fox, Edward, Lawrence Steinman, Hans‐Peter Hartung, et al.. (2022). Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010). Neurology. 98(18_supplement). 1 indexed citations

Cree, Bruce, Edward Fox, Hans‐Peter Hartung, et al.. (2022). Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009). Neurology. 98(18_supplement). 1 indexed citations

Lovett‐Racke, Amy E., Yuhong Yang, Yue Liu, et al.. (2021). B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. Journal of Neuroimmunology. 359. 577676–577676. 13 indexed citations

Lewis, Sandy, Sibyl Wray, Emily Evans, et al.. (2021). Patients’ Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews. Neurology and Therapy. 10(2). 887–904.

10.

Pelletier, Daniel, Douglas L. Arnold, Ann Bass, et al.. (2020). Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up. Multiple Sclerosis Journal. 26. 43–44. 2 indexed citations

11.

Wijmeersch, Bart Van, B. Singer, Aaron Boster, et al.. (2019). Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal. 26(13). 1719–1728. 16 indexed citations

12.

Wray, Sibyl, François Jacques, Tamara Miller, et al.. (2019). Treatment Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study (P3.2-097). Neurology. 92(15_supplement). 1 indexed citations

13.

Fox, Edward, David Brassat, Raed Alroughani, et al.. (2017). Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006). Neurology. 88(16_supplement). 2 indexed citations

14.

Boyко, Alexey, Michael Barnett, David Brassat, et al.. (2017). Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332). Neurology. 88(16_supplement). 1 indexed citations

15.

Selmaj, Krzysztof, Mario Habek, Ann Bass, et al.. (2017). Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study (P5.338). Neurology. 88(16_supplement). 6 indexed citations

16.

Wray, Sibyl, Alexey Boyко, Tiffany J. Braley, et al.. (2015). Administration of Alemtuzumab on Nonconsecutive Days Does Not Impact Infusion-Associated Reactions, Efficacy, or Lymphocyte Depletion (P7.277). Neurology. 84(14_supplement). 2 indexed citations

17.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

18.

Singer, B., Sibyl Wray, Tamara Miller, et al.. (2012). Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 1(2). 87–94. 14 indexed citations

19.

Bandari, Daniel S., Daniel Wynn, Tamara Miller, et al.. (2012). Rebif® Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. Multiple Sclerosis and Related Disorders. 2(1). 45–56. 5 indexed citations

20.

Farel, Paul B., et al.. (1992). Neuron addition in the postmetamorphic frog. Experimental Gerontology. 27(1). 111–124. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact